Compare LC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LC | STOK |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | 128 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2014 | 2019 |
| Metric | LC | STOK |
|---|---|---|
| Price | $19.96 | $32.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $22.67 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 1.5M | 930.2K |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.62 | N/A |
| EPS | ★ 0.89 | 0.68 |
| Revenue | ★ $1,296,102,000.00 | $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | $16.10 | N/A |
| P/E Ratio | ★ $22.32 | $47.31 |
| Revenue Growth | 16.98 | ★ 1128.17 |
| 52 Week Low | $7.90 | $5.35 |
| 52 Week High | $20.94 | $38.69 |
| Indicator | LC | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 58.66 |
| Support Level | $18.98 | $30.17 |
| Resistance Level | $20.94 | $35.40 |
| Average True Range (ATR) | 0.68 | 2.13 |
| MACD | 0.23 | 0.31 |
| Stochastic Oscillator | 78.92 | 61.10 |
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.